1. Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL.
- Author
-
Strati, Paolo, Ahmed, Mohamed Amin, Nastoupil, Loretta J., Feng, Lei, Hagemeister, Fredrick B., Fayad, Luis E., Rodriguez, Maria A., Samaniego, Felipe, Wang, Michael, Westin, Jason R., Lee, Hun J., Iyer, Swaminathan P., Parmar, Simrit, Ahmed, Sairah, Nair, Ranjit, Steiner, Raphael E., Noorani, Mansoor, Flowers, Christopher R., Davis, R. Eric, and Fowler, Nathan H.
- Subjects
MANTLE cell lymphoma ,PROGRESSION-free survival - Abstract
In 2 randomized phase 3 trials BR resulted in longer progression-free survival (PFS) than frontline R-CHOP in patients with indolent and mantle cell lymphoma. However, in subset analyses of follicular lymphoma (FL), the results were incongruent. We conducted a retrospective matched-pair analysis to compare the outcome of patients with advanced stage FL, receiving frontline BR (N = 73) or R-CHOP (N = 73), matched by age, gender, stage, and FL International Prognostic Index score. On multivariable analysis, baseline maximum standardized uptake value (SUV
max ) >13 was associated with use of R-CHOP (p =.001). After a median follow-up of 69 months for the BR arm and 126 months for the R-CHOP arm, 5-year PFS was 80% and 70%, respectively (p =.07). After adjusting for SUVmax >13, the trend for better PFS in BR was not maintained. Prospective studies are needed to validate the role of pretreatment SUVmax as a stratification factor in future randomized therapeutic trials in FL. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF